Exposure history impacts universal flu vax development, research says; Medigene touts early AML data;

> A new study suggests that immune system history could play a big role in scientists' ability to create a universal flu vaccine. Report

> Medigene unveiled "promising" early data from ongoing dendritic cell vaccine trials in patients with acute myeloid leukemia. Release

> The development of a new vaccine is one objective of a recently announced strategy to defeat tuberculosis as a public health threat by 2035. Report

> A University of Helsinki study demonstrated the potential for scientists to predict influenza evolution and create better seasonal vaccines by using genomic information from virus strains in circulation. Report

> Ann Arbor, MI-based NanoBio said its intranasal nanoemulsion adjuvanted chlamydia vaccine demonstrated efficacy in a mouse challenge. Release

And Finally... Science Friday examined the etymology of the word "vaccine." More

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.